Filtered By:
Condition: Stroke
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Dabigatran and Warfarin are Both Used for Stroke-prevention in Patients with AF but their Side effects Differ
NEW YORK (Reuters Health) – Dabigatran and warfarin offer similar stroke-prevention efficacy in patients with atrial fibrillation (AF), but their side effect profiles differ, according to a systematic review and meta-analysis of real-world clinical practice. “There could be many reasons for the differences in our findings, such as differences in the quality of evidence of... [Read More]
Source: The Hospitalist - February 19, 2016 Category: Hospital Management Authors: Will Boggs MD, Reuters Health Tags: Clinical Education Hospitalist Patient Care atrial fibrillation Dabigatran stroke warfarin Source Type: research

Warfarin-Resistant Deep Vein Thrombosis during the Treatment of Acute Ischemic Stroke in Lung Adenocarcinoma
A 66-year-old man with acute ischemic stroke in the setting of lung adenocarcinoma developed acute-onset deep vein thrombosis (DVT) of the lower limbs after changing to warfarin from a heparin combination. The diagnosis of warfarin-resistant DVT was established based on the laboratory data and clinical evaluation. Heparin administration resulted in good control of thrombin regulation. Cancer patients are at high risk of venous thromboembolism, and the combination of these 2 conditions is known as Trousseau's syndrome.
Source: Journal of Stroke and Cerebrovascular Diseases - June 21, 2016 Category: Neurology Authors: Hiroyuki Naito, Shiro Aoki, Naoko Sumi, Kazuhide Ochi, Naohisa Hosomi, Hirofumi Maruyama, Masayasu Matsumoto Tags: Case Studies Source Type: research

Recurrent cryptogenic stroke in young adult linked to congenital left ventricular diverticulum
A 47-year-old man had an acute ischemic stroke (IS); brain MRI revealed multiple silent old IS (figure 1A). A comprehensive workup, including prolonged cardiac monitoring (cumulated duration of 25 days) and cardiac transthoracic/transesophageal echography, was negative. Eleven months later, despite statin and aspirin therapy, a new symptomatic embolic IS of undetermined source occurred (figure 1B). Cardiac MRI1 revealed a left apical dyskinetic saccular evagination (figure 2, A–C) consistent with a congenital left ventricular diverticulum confirmed on left ventriculography (figure 2D) and the presumed source of recur...
Source: Neurology - November 13, 2016 Category: Neurology Authors: Gaillard, N., Targosz, F., Bertrand, J. L., Sablot, D., Bensalah, Z. M. Tags: Stroke in young adults, Cardiac, Embolism, Infarction NEUROIMAGES Source Type: research

Letter by Chen et al Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Chen Chen, Dongze Li, Lixia Deng Tags: Arrhythmias, Heart Failure, Complications, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Response by Di Tullio et al to Letter Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Marco R. Di Tullio, John L.P. Thompson, Shunichi Homma, for the WARCEF Investigators Tags: Heart Failure, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study
Conclusions We found no reduction in incidence of AF-related vascular events since publication of the BAFTA trial. A third of all disabling/fatal strokes occur in non-anticoagulated patients with known prior AF.
Source: Journal of Neurology, Neurosurgery and Psychiatry - December 14, 2016 Category: Neurosurgery Authors: Yiin, G. S. C., Howard, D. P. J., Paul, N. L. M., Li, L., Mehta, Z., Rothwell, P. M., on behalf of the Oxford Vascular Study Tags: JNNP Patients' choice, Open access, Stroke Cerebrovascular disease Source Type: research

Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR
Current guidelines allow the administration of intravenous recombinant tissue plasminogen activator (IV r-tPA) to warfarin-treated patients with acute ischemic stroke (AIS) who have an international normalized ratio (INR) of ≤1.7. However, concerns remain about the safety of using IV r-tPA in this situation due to a conceivable risk of symptomatic intracranial hemorrhage (sICH), lack of dedicated randomized controlled trials and the conflicts in the available data. We aimed to determine the risk of sICH in warfarin-tr eated patients with subtherapeutic INR who received IV r-tPA for AIS in our large volume comprehensive center.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Ashkan Mowla, Aurangzeb Memon, Seyed-Mostafa Razavi, Navdeep S. Lail, Caila B. Vaughn, Pegah Mohammadi, Robert N. Sawyer, Peyman Shirani Source Type: research

Stroke risk 'higher at start of warfarin treatment'
Conclusion This study has found that warfarin was associated with an increased risk of ischaemic stroke during the first 30 days of treatment. After 30 days of treatment, warfarin was associated with a decreased risk of stroke. However, this study has a number of limitations that should be considered: All information was from patient records, which means that it wasn't subject to recall bias, but the information may not be complete – we do not know if, for example, people took the medication they were prescribed. There may be other factors (confounders) that explain the association seen. In particular, the ba...
Source: NHS News Feed - December 19, 2013 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

IJERPH, Vol. 19, Pages 1078: Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
Conclusions: The direct medical cost of stroke is substantial, with AF-stroke having a higher median cost per stroke care. DOACs were cost effective in the treatment of AF-related stroke in UKMMC.
Source: International Journal of Environmental Research and Public Health - January 19, 2022 Category: Environmental Health Authors: Siti Norain Azahar Saperi Sulong Wan Asyraf Wan Zaidi Norliza Muhammad Yusof Kamisah Norliana Masbah Tags: Article Source Type: research

Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
This study provides Class II evidence that in patients with non-valvular atrial fibrillation suffering an ischemic stroke while being treated with a DOAC, continuing treatment with that DOAC is more effective at preventing recurrent ischemic stroke than switching to a different DOAC or to warfarin.PMID:37225430 | DOI:10.1212/WNL.0000000000207422
Source: Atherosclerosis - May 24, 2023 Category: Cardiology Authors: Yiu Ming Bonaventure Ip Kui Kai Lau Ho Ko Lucas Lau Alan Yao Grace Lai-Hung Wong Terry Cheuk-Fung Yip Xinyi Leng Howard Chan Helen Chan Vincent Mok Yannie O Y Soo David Seiffge Thomas W Leung Source Type: research

Abstract 223: National and Regional Trends in Hospitalizations for Hemorrhagic Stroke after Acute Myocardial Infarction in the United States: 1999-2010 Poster Session II
Conclusions: From 1999 to 2010, the overall hospitalization rates of hemorrhagic stroke after AMI were relatively stable without significant changes across all subgroups. Thirty-day mortality rates remained largely unchanged over time. Stroke risk in the stroke belt was not found significantly higher comparing with non-stroke belt states.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Shi, R., Wang, Y., Lichtman, J. H., Dharmarajan, K., Masoudi, F. A., Dodson, J. A., Chen, J., Chaudhry, S. I., Spertus, J. A., Nallamothu, B. K., Krumholz, H. M. Tags: Poster Session II Source Type: research

Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia.
In conclusion, the practice of stroke neurologists is consistent with and supports the available evidence from observational studies on the time of initiation of NOACs. Our findings provide a guide for clinicians who manage nvAF-related stroke until more robust evidence from randomized controlled trials is available. PMID: 31531241 [PubMed]
Source: Neurology Research International - September 20, 2019 Category: Neurology Tags: Neurol Res Int Source Type: research

Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation —A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation
Discussion: AREST will offer randomized controlled trial data about timeliness and safety of anticoagulation in AIS patients with AF.Clinical Trial Registration:www.ClinicalTrials.gov, identifier NCT02283294.
Source: Frontiers in Neurology - September 19, 2019 Category: Neurology Source Type: research

Healthcare costs before and after stroke in non-valvular atrial fibrillation patients who initiated treatment with rivaroxaban or warfarin.
CONCLUSIONS: Total all-cause costs of care increased in the post-stroke period, and particularly in the patients treated with warfarin relative to those treated with rivaroxaban. The lower rate of stroke in the rivaroxaban cohort suggests that greater pre- to post-stroke cost increases result from more strokes occurring in the warfarin cohort. PMID: 33499689 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 29, 2021 Category: Health Management Tags: J Med Econ Source Type: research